LOW PLATELETCRIT IS ASSOCIATED WITH REDUCED PROGRESSION – FREE AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA NISKI TROMBOKRIT JE POVEZAN SA SMANJENIM PREŽIVLJAVANJEM BEZ PROGRESIJE I OPŠTIM PREŽIVLJAVANJEM KOD HRONIČNE LIMFOCITNE LEUKEMIJE

Creative Commons License

ÖZBALCI D., ALANOĞLU E. G., FİNDOS E., Eroglu H. N.

Journal of Medical Biochemistry, cilt.42, sa.2, ss.274-281, 2023 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.5937/jomb0-39375
  • Dergi Adı: Journal of Medical Biochemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, Central & Eastern European Academic Source (CEEAS), EMBASE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.274-281
  • Anahtar Kelimeler: chronic lymphocytic leukaemia, overall survival, Plateletcrit, prognosis
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Süleyman Demirel Üniversitesi Adresli: Evet

Özet

Background: Alterations of plateletcrit and mean platelet volume (MPV) and pathogenesis of chronic lymphocytic leukaemia (CLL) have been linked to various inflammatory disorders. The prognostic impact of plateletcrit and MPV were evaluated. Methods: MPV and plateletcrit levels of both CLL and control group were compared and then in CLL patients, additional diseases, leukocyte count, platelet count, lactate dehydrogenase, Rai stage, progression-free and overall survival, mutations, if any, and chemotherapy, if any, were recorded. Then, the relationship between MPV and plateletcrit values and these parameters were evaluated in CLL patients. Results: Platelet and plateletcrit values were found to be significantly lower in CLL patients than the control group (p<0.001) for both. Plateletcrit and MPV values of patients who did not receive chemotherapy were higher than those who received chemotherapy (p=0.03, p=0.02, respectively). Being over 75 years old, plateletcrit value less than 0.1565 %, platelet level below 175 x 109/L, and leukocyte count greater than 53.5 x 109/L was found to significantly reduce overall survival. Male gender, each stage increase, plateletcrit less than 0.1565 % and leukocyte count greater than 53.5 x 109/L was related to reduce treatment-free survival in CLL patients. Conclusions: Plateletcrit can be a viable prognostic marker for defining both treatment free and overall survival.